Streamlining event ascertainment in cancer randomised controlled trials: accuracy of the SCORE-CVD-MI algorithm using health system data in a large prostate cancer trial

Clicks: 1
ID: 323293
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #188 of 282 articles by views in European heart journal supplements : journal of the European Society of Cardiology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 282 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Cardiovascular safety is critical in oncology trials. Health system data (HSD) can facilitate event detection while minimising site burden. Purpose We aimed to evaluate the feasibility of ascertaining myocardial infarction (MI) in a prostate cancer clinical trial using HSD and a recently developed phenotyping algorithm. Methods Participants from a large prostate cancer trial were linked to Hospital Episode Statistics – Admitted Patient Care (HES-APC), which contains all NHS inpatient admissions in England. MI events were identified from HES-APC using two approaches: conventional code lists (cHES) and the SCORE-CVD-MI phenotyping algorithm (SCVD). Agreement with trial-reported MI was assessed. Results A total of 6,901 trial participants with 44,405 HES-APC episodes were included. Over a median follow-up of 21.2 months (IQR 5.7-65.9), 91 MIs were reported in 90 (1.3%) trial participants. SCVD identified 84 (92.3%) of these events, and cHES 83 (91.2%). Agreement between SCVD and the trial was moderate-to-strong (kappa: 0.79, 95% CI: 0.77 to 0.82), and higher than between cHES and the trial (kappa: 0.72, 95% CI: 0.70 to 0.75) (p=0.001). Sensitivity and specificity of SCVD were 0.99 (95% Credible Interval 0.99-0.99) and 0.95 (95% Credible Interval 0.88-0.99). Time-to-first-event analysis were comparable between SCVD and trial [HRpatient-strata (95% CI): 1.23 (0.93-1.64), p = 0.148]. Conclusions Identification of MI admissions using HES-APC was feasible and accurate in a prostate cancer trial. The SCVD phenotyping algorithm outperformed the conventional approach, offering a promising and reproducible method for cardiovascular safety monitoring in oncology trials.Figure 1 Figure 2
Reference Key
openalex_W7172309233 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors R Gonzalez-Manzanares, S Love, S Lessels, J Farrell, R E Langley, D Gilbert, N James, L C Brown, M Murray, M Sydes
Journal European heart journal supplements : journal of the European Society of Cardiology
Year 2026
DOI
10.1093/eurheartjsupp/suag097.212
URL
https://doi.org/10.1093/eurheartjsupp/suag097.212
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.